The CCK8 results revealed that PPARδ agonist promoted HCC cells proliferation in a dose-dependent manner (Fig. 3C and D), and GSK3787 reversed the proliferation effect of GW501516 (Fig. 3E and F). The gene discussed is PPARD; the disease is hepatocellular carcinoma.